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Radiological Prediction of Positive Circumferential Resection Margin in 
Oesophageal Cancer 
 
 
 
 
 
    
Abstract 
Purpose 
A positive circumferential resection margin (CRM) is regarded as a poor 
prognostic indicator in oesophageal cancer (OC) but its prediction can be 
challenging.  MRI is used to predict a threatened CRM in rectal cancer but is 
not commonly performed in OC unlike PET/CT, which is now routinely used.  
Therefore, this study assessed the additional predictive value of PET-defined 
tumour variables compared with EUS and CT T-stage.  The prognostic 
significance of CRM status was also assessed. 
 
Materials and Methods  
This retrospective study included 117 consecutive patients [median age 64.0 
(range 24-78), 102 males, 110 adenocarcinomas, 6 squamous cell carcinoma 
(SCC), 1 neuro-endocrine] treated between 1st March 2012 and 31st July 2015.  
A binary logistic regression model tested 5 staging variables; EUS T-stage (T2 
vs T3), CT T-stage (T2 vs T3), PET metabolic tumour length (MTL), PET 
metabolic tumour width (MTW) and the maximum standardised uptake value 
(SUVmax). 
 
    
Results 
The CRM was positive in 43.6%.  Sixty-seven (57.3%) patients received neo-
adjuvant chemotherapy (NACT), 31 patients (26.5%) underwent surgery alone 
and 19 patients (16.2%) had neo-adjuvant chemo-radiotherapy (NACRT).  
Median overall survival (OS) was 36.0 months (95% confidence interval (CI) 
24.1-47.9) and the 2-year OS was 55.4%.  A binary logistic regression model 
showed EUS ≥T3 tumours were independently and significantly more likely to 
have a positive CRM than EUS ≤T2 tumours (HR 5.188, 95% CI 1.265-21.273, 
p=0.022).  CT T-stage, PET MTL, PET MTW and SUVmax were not significantly 
associated with CRM status (p=0.783, 0.852, 0.605 and 0.413, respectively).  
There was a significant difference in OS between CRM positive and negative 
groups (X2 4.920, df 1, p=0.027). 
 
Conclusion 
Advanced EUS T-stage is associated with a positive CRM, but PET-defined 
tumour variables are unlikely to provide additional predictive information.  This 
study demonstrates the continued benefit of EUS as part of a multi-modality 
OC staging pathway. 
 
 
 
    
Introduction 
The impact of circumferential resection margin (CRM) involvement on patient 
outcome in oesophageal cancer (OC) has been widely reported. [1-3]  Although 
some studies have failed to demonstrate the prognostic significance of an 
involved or threatened CRM [4, 5], it is now widely accepted that a positive 
resection margin is important. [6]  Analysis from the USA Intergroup 113 trial 
investigated the effect of CRM status on survival. [7]  Thirty-two percent of 
patients with a R0 resection were alive and disease-free at 5 years, compared 
to only 5% survival in those with a R1 resection. 
 
Prediction of pathological CRM involvement could influence treatment 
selection, potentially improving overall survival (OS) and recurrence rates.  
Clinicians may have a lower threshold for offering neo-adjuvant therapy to 
patients at risk.  In general, fit patients with tumours of stage T3/T4a, N0/N1, or 
T1/T2 N1, are considered for neo-adjuvant therapy.  Following publication of 
MRC OE02, the current standard treatment in the UK is neo-adjuvant 
chemotherapy (NACT) followed by surgery, although neo-adjuvant 
chemoradiotherapy (NACRT) is gaining support and may eventually become 
standard of care. [8-10] 
 
In the UK, patients with OC are initially staged with contrast-enhanced 
computed tomography (CT) to exclude unresectable disease or distant 
metastases.  Patients with potentially curable disease then routinely undergo 
    
EUS and positron emission tomography (PET) combined with CT (PET/CT) for 
more detailed staging. [11]  PET/CT is predominately used to exclude distant 
metastases not demonstrated on CT, and for treatment planning.  Image 
features including metabolic tumour length (MTL), metabolic tumour width 
(MTW) and the maximum standardised uptake value (SUVmax) are prognostic 
indicators of survival and treatment response. [12, 13] 
 
There is currently limited evidence investigating the association between PET-
defined tumour variables and a threatened CRM.  MRI accurately predicts a 
positive CRM in rectal cancer [14], however early MRI studies in OC 
encountered initial difficulties because the examination is technically 
challenging. [15]  Alternative methods are required to improve CRM prediction 
in OC.  PET-defined tumour variables may provide additional predictive value 
when assessing the CRM. 
 
Therefore, this study investigated the additional value of PET-defined tumour 
variables (MTL, MTW and SUVmax) compared with EUS and CT T-stage, to 
predict a threatened CRM.  The prognostic significance of a positive CRM was 
also assessed. 
 
 
    
Methods and Materials 
 
Patient Cohort 
 
A retrospective cohort study was conducted in consecutive patients with 
biopsy-proven OC treated between 1st March 2012 and 31st July 2015.  
Patients with gastro-oesophageal junction (GOJ) tumours were included. 
Clinical, radiological, surgical and pathological data were reviewed from a 
prospectively maintained surgical upper gastro-intestinal (GI) cancer database 
in a University teaching hospital.   
 
Patients were identified for inclusion at the centralised Regional Upper GI 
Cancer MDT and deemed to have potentially curable disease following clinical 
examination, upper GI endoscopy and radiological staging investigations.  All 
patients underwent PET/CT examination in the same institution using the same 
scanner and protocol and had surgical resection (with or without neo-adjuvant 
therapy) in the centralised regional service.  Institutional review board granted 
approval for the study (13//DMD5769).  Patients were excluded from the study 
if the patient had incomplete staging, salvage oesophagectomy after radical 
radiotherapy or an ‘open-and-close’ procedure (aborted resection).  Following 
exclusions, 117 patients were included in the study.   
 
Radiological Staging 
 
    
Radiological staging was classified according to International Union Against 
Cancer (UICC) Tumour Node Metastasis (TNM) 7th edition. [16]  PET/CT 
examinations were reported by Consultant Radiologists with minimum of 5 
years’ experience.  EUS was performed in 3 centres by 4 experienced 
endosonographers. 
 
CT Protocol  
 
CT was performed either in the host institution of the centralised service, or in 
the local referring hospitals, according to Royal College of Radiologists 
guidelines. [11]  All CT examinations were reviewed at the Regional Upper GI 
MDT, and deemed to be of a satisfactory technical standard.  At the host 
institution, CT was performed with a GE HD 750 Discovery 64-slice scanner 
(GE Healthcare, Pollards Wood, Buckinghamshire, UK).  CT images were 
acquired by a helical acquisition with collimation of 40mm, pitch 0.984:1 and 
tube rotation speed of 0.4 s.  Tube output was 120 kVp with smart mA dose 
modulation between 60-600 mA.  Slice thickness was 0.625 mm with 
acquisition of images on soft and lung algorithms with 3 mm reconstructions.  
Approximately 500 ml of water was given orally.  Between 100-150 ml of 
Niopam 300 was given intravenously. 
 
EUS Technique 
 
    
At the host institution, an initial endoscopic examination was performed using a 
9 mm diameter Olympus Paediatric gastroscope (Olympus, Southend, UK) to 
assess the degree of oesophageal luminal stenosis.  Patients with an 
estimated oesophageal luminal diameter of less than 15 mm underwent 
examination using the smaller-diameter MH-908 oesophagoprobe, and where 
there was no luminal stenosis, the standard UM-2000 echoendoscope was 
used (Olympus, Southend, UK). The type of echoendoscope used was at the 
discretion of the endoscopist.  No significant difference in accuracy exists 
between the 2 echoendoscopes. [17]  The primary oesophageal tumour was 
assessed, together with an evaluation of the para-oesophageal anatomical 
structures as described previously. [18] 
 
PET/CT Protocol 
 
Patients were fasted for at least 6 hours prior to tracer administration. Serum 
glucose levels were routinely checked and confirmed to be less than 7.0 
mmol/L. Patients received a dose of 4 MBq of 18F-FDG per kilogram of body 
weight.  Uptake time was 90 minutes. 18F-FDG PET/CT imaging was performed 
with a GE 690 PET/CT scanner (GE Healthcare, Buckinghamshire, UK).  CT 
images were acquired in a helical acquisition with a pitch of 0.98 and a tube 
rotation speed of 0.5 s. Tube output was 120 kVp with output modulation 
between 20 and 200 mA. Matrix size for the CT acquisition was 512 x 512 
pixels with a 50 cm field of view.  No oral or intravenous contrast was 
administered. PET images were acquired at 3 minutes per field of view.  The 
    
length of the axial field of view was 15.7 cm.  Images were reconstructed with 
the ordered subset expectation maximisation algorithm, with 24 subsets and 2 
iterations.  Matrix size was 256 x 256 pixels, using the VUE Point ™ time of 
flight algorithm. (Fig. 1) 
 
PET-Defined Tumour Variables 
 
PET MTL is defined as the maximum perceived cranio-caudal length of primary 
tumour and was measured on a GE advantage windows 4.5 reporting 
workstation (GE healthcare, Buckinghamshire, UK) by a single observer with 5-
years’ experience of PET research.  The observer was blinded to the 
histopathological results and used consistent methodology.  The maximum 
intensity projection images were rotated to visualise the greatest length of 
tumour and MTL was measured in mm.  MTW is defined as the maximum 
perceived width of primary tumour perpendicular to the MTL and was 
measured in mm.  The SUVmax of the primary tumour represents the voxel with 
the highest FDG-uptake value and is automatically returned by the software, 
based on an adaptive threshold method of 42%.  Non-avid tumours were 
recorded as a value of 0.0. 
 
Clinical Management 
 
Administration of neo-adjuvant therapy was dependent on radiological stage of 
disease, regional MDT discussion, perceived medical fitness and patient 
    
wishes.  Most patients received NACT, usually by two cycles of 80mg/m2 
cisplatin and 1000 mg/m2 of 5-fluorouracil (5-FU) for 4 days. A minority 
received four cycles of epirubicin (50 mg/m2), cisplatin (60 mg/m2) and 5-FU 
(200 mg/m2).  For NACT, patients typically receive 2 cycles of oxaliplatin (130 
mg/m2) and capecitabine (625mg/m2) as induction NACT followed by 45 Gy of 
radiotherapy administered in 25 fractions over a 5-week period with concurrent 
chemotherapy.  All surgery was performed by specialist upper GI surgeons in a 
centralised tertiary referral unit.  Trans-hiatal surgery was selected for patients 
with tumours of the distal oesophagus, in whom it was considered that a 
thoracotomy may carry an unacceptable risk of respiratory complications due to 
poor performance status. 
 
Histopathological Analysis 
 
Histopathological examination of the resection specimen was performed by a 
Consultant Histopathologist with a special interest in Upper GI malignancy.  
The primary outcome of the study was a positive CRM.  There are two widely 
agreed definitions of CRM status.  The Royal College of Pathologists (RCPath) 
define a positive (or threatened) CRM as tumour within 1 mm of the resection 
margin. [19] (Fig. 2) The College of American Pathologists (CAP) define tumour 
at the cut margin of the resection as positive. [20]  Only the RCP definition is 
used in the UK, and a comparison between the two is not performed in this 
study. Tumour Regression Grade (TRG) was assigned according to the 
Mandard Classification in patients who received neo-adjuvant therapy. [21] 
    
 
Survival Data 
 
The secondary outcome of the study was OS, defined in months, measured 
from the date of diagnosis.  Survival data was obtained from the Cancer 
Network Information Service Cymru (CaNISC, Velindre NHS Trust, Wales).  
Each patient was followed up 3-monthly in the first year and 6-monthly 
thereafter, until either 5 years or death. 
 
Statistical analysis 
 
Categorical variables are summarised as frequency (percentage) and 
continuous variables as median (range).  Chi-square tests assessed 
differences between EUS T-stage, CT T-stage, TRG and treatment type with 
CRM status.  EUS and CT T-stage was separated into ≤T2 vs ≥T3 prior to 
analysis given that relatively few patients present with T1 and T2 tumours.  The 
agreement between EUS and CT T-stage was assessed with the weighted 
kappa statistic (Kw). [22]  Mann-Whitney U tests assessed differences between 
PET MTL, PET MTW and SUVmax with CRM status.  Multi-variate analysis was 
performed by entering the 5 variables into binary logistic regression model.  
The model was powered using an event per variable (EPV) ratio of at least 10, 
with an event defined as a positive CRM. [23]  A log-rank test assessed 
differences in OS between CRM status.  A p-value of <0.05 was considered 
    
statistically significant. Data analysis was performed using SPSS version 23 
(IBM, Chicago, IL, USA). 
 
    
Results 
Patient characteristics are detailed in Table 1.  The median age of the cohort 
was 64.0 years (range 24-78).  Median survival was 36.0 months (95% 
confidence interval (CI) 24.1-47.9) and 2-year OS was 55.4%.  The radiological 
and pathological TN classification of disease is detailed in Table 2.  No patients 
in the cohort were classified as having distant metastatic (M1) disease 
following radiological staging investigations. 
 
The positive CRM rate in patients treated with NACT, surgery alone and 
NACRT was 50.7%, 38.7% and 26.3%, respectively. There was no significant 
difference in positive CRM rates between these treatments (X2 4.001, df 2, 
p=0.135). 
 
Most tumours were staged T3 by EUS and CT (78.6% and 70.9%, 
respectively) with relatively few early cancers (T1 & T2). (Table 2)  There was 
relatively weak agreement between EUS and CT T-stage (Kw 0.424, 95% CI 
0.273-0.575, p<0.001).  The median PET MTL was 48.1 mm (range 0.0-88.0), 
the median PET MTW was 23.5 mm (0.0-47.8) and the median SUVmax was 
11.1 (0.0-70.9). 
 
A chi-square test demonstrated EUS ≥T3 tumours were more likely to have a 
positive CRM than EUS ≤T2 tumours (X2 4.962, df 1, p=0.026). (Table 3)  CT 
T-stage, PET MTL, PET MTW and SUVmax were not significantly associated 
with CRM status (p=0.161, 0.852, 0.605 and 0.413, respectively). In addition, 
    
the TRG was significantly associated with CRM status (X2 14.042, df 4, 
p=0.007). 
 
EUS ≤T2 vs ≥T3, CT ≤T2 vs ≥T3, MTL and MTW and SUVmax were entered 
into a binary logistic regression model. (Table 4)  The EPV ratio was 10.2. EUS 
≤T2 vs ≥T3 was significantly and independently associated with CRM 
involvement (HR 5.188, 95% CI 1.265-21.273, p=0.022). 
 
There was a significant difference in OS for CRM status (X2 4.920, df 1, 
p=0.027). (Fig. 3) The mean OS for patients with negative CRM resections was 
39.6 months (95% CI 34.5-44.7) compared to 30.9 months (25.6-36.2) for 
those with a positive CRM. 
 
 
 
    
Discussion 
 
This study has shown that EUS ≥T3 is a significant, independent predictor of a 
positive CRM but PET-defined tumour variables may not have any additional 
value for predicting pathological CRM involvement.  These results highlight the 
continued benefit of EUS in the OC staging pathway and validate previous 
results from our centre, which demonstrated that EUS ≥T3 has an increased 
risk of CRM involvement compared to tumours ≤T2. [24]  Studies investigating 
the association of radiological staging investigations and CRM are limited in 
frequency. 
 
Reid et al found a positive CRM to be independently and significantly 
associated with OS for all pT-stages. [24]  Advanced endoscopic ultrasound 
(EUS) T-stage was independently associated with a positive CRM, with an 
almost 25-fold increased risk of a threatened CRM, once a tumour was 
classified T3 or greater.  The recruitment period for Reid et al ended in 
February 2012, therefore these results provide some internal validation in a 
new, independent cohort of patients. 
 
Sagar et al produced the first major paper that described the prognostic effect 
of CRM involvement in OC. [2]  A systematic review and meta-analysis by 
Chan et al found significant 5-year survival differences in patients with a 
positive CRM. [1]  The overall 5-year mortality rate was significantly different 
according to both criteria (odds ratio 4.02 and 2.52, respectively).  Our study 
    
also shows a significant difference in OS between positive and negative CRM 
groups.  Chan et al highlighted differences between the American and British 
definitions of CRM involvement.  Rates of involvement were 15.3% according 
to the CAP definition, and 36.5% according to the RCP definition.  Only the 
RCPath definition is used in this current study. 
 
EUS provides the most accurate T-stage assessment. [25]  Pooled sensitivities 
of 82-92% and an accuracy of 83% are described. [26, 27]  This modality 
benefits from superior contrast resolution compared to PET and CT. PET 
variables are unlikely to provide sufficiently detailed anatomy to predict CRM 
involvement, due to its inherently limited spatial resolution. [28]  Similarly, CT is 
poor at differentiating individual layers of the oesophageal wall making it 
inferior to EUS.  There was relatively weak agreement between EUS and CT T-
stage, which confirms this finding.  CT T-stage was not significantly associated 
with CRM status in this study. 
 
Identification of a threatened CRM from radiological staging investigations is 
likely to benefit patient outcome.  In the UK, PET/CT and EUS are generally 
only performed prior to treatment initiation and are not repeated post-neo-
adjuvant therapy, as in other countries including the USA.  Two strategies for 
individualising treatment exist; the first is the decision to use neo-adjuvant 
therapy if the CRM is threatened and the second is the decision to operate 
post-neo-adjuvant therapy.  One study did not show any benefit when surgical 
resection was performed following a complete response on PET/CT. [29]  The 
    
former strategy of predicting CRM involvement prior to treatment initiation is 
more suited to the UK staging pathway, given that PET/CT and EUS are not 
repeated.  Furthermore, results of this study have shown that patients with a 
good response are significantly less likely to have a positive CRM following 
resection. 
 
Treatment selection can influence the positive CRM rate.  NACRT may improve 
the number of R0 resections (a microscopically margin-negative resection) 
compared to NACT, with R0 rates of between 87.5% and 92.0% described in 
the literature. [24, 30]  This current study did not demonstrate a significantly 
different positive CRM rate between treatments, but there were small numbers 
of patients in the NACRT group. 
 
The positive CRM rate in this patient cohort is high but comparable to those 
quoted in the National Oesophago-Gastric Cancer Audit. [31]  A trans-hiatal 
approach was employed in 47.9% of patients in this cohort.  This is significantly 
higher than the national rate of 4%, which could in turn explain the relatively 
high positive CRM rate.  The surgeons in our institution employ this technique 
because the population of patients on which they operate tend to have 
significant co-morbidities attributable to the effects of poor lifestyle and 
deprivation. [32]  Morbidity rates are reduced following trans-hiatal resection 
compared to a trans-thoracic approach. [33] 
 
 
    
 
Strengths of Study 
 
All patients with OC in this study were managed by an experienced MDT, 
serving a stable population of approximately 1.5 million.  The staging pathway 
has not altered during the study period therefore all patients have been staged 
consistently.  All PET/CT examinations were performed using the same 
scanner and protocol.  Operations were all performed as part of a centralised 
service by Upper GI cancer surgeons.  Oesophageal resection specimens were 
assessed and reported by a Consultant Histopathologist with an interest in 
upper GI cancer, and findings routinely discussed at MDT.  The study is 
powered according to the EPV and the results of the uni-variate analysis did 
not affect variable selection for the multi-variate regression model, thus 
preventing an over-fitted model. [34] 
 
Limitations 
 
A confounding factor in this analysis is the technique of the surgeon and the 
approach employed.  The surgical approach used was considered the best for 
the patient and most likely to result in a positive outcome.  In line with national 
data, the two most common types of oesophagectomy were used; trans-
thoracic (Ivor-Lewis) and trans-hiatal.  The surgeons work together within a 
centralised system so their techniques are likely to be similar.  This patient 
cohort is relatively heterogeneous.  Patients with differing stage of disease, 
    
treatment type, histology and response to treatment were included.  In general, 
OC patients are a heterogeneous cohort and introduction of some sample 
heterogeneity into research studies can be unavoidable.  This reflects the 
intention-to-treat basis of clinical research, but can introduce potential bias into 
the results.  Three treatment types are included in this study, which have 
differing effects on CRM status, as evidenced by the CROSS trial. [30]  
However, only 19 patients had a complete (TRG 1, n=9) or excellent (TRG 2, 
n=10) response to neo-adjuvant therapy, which suggests that the disease did 
not change significantly in the majority of cases.  EUS examinations were 
performed by different endosonographers, which may cause variability in T-
stage accuracy, but again adds weight to the generalisability of the results. 
 
 
Conclusion  
A positive CRM is an important prognostic indicator of survival.  Prior 
knowledge of a threatened CRM would assist clinicians with management 
decisions.  This study has shown that EUS ≥T3 is a significant independent 
predictor of a positive CRM, but PET-defined tumour variables are unlikely to 
add additional predictive value regarding CRM status. 
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Figure Legends 
 
Figure 1. Axial fused PET/CT image of a distal oesophageal adenocarcinoma 
which had a positive CRM following surgical resection. 
 
Figure 2. A selected radial EUS image of the distal oesophageal 
adenocarcinoma (T, calipers), in close proximity to the descending thoracic 
aorta (AO).  A corresponding medium-power magnification of the tumour 
demonstrates a positive CRM (white arrow), with stained tumour cells at the cut 
resection margin. 
 
Figure 3. Kaplan-Meier plot demonstrates a significant difference in overall 
survival between CRM status (X2 4.920, df 1, p=0.027). Patients with a positive 
CRM have worse OS. 
    
Table 1. Characteristics of Patient Cohort 
Demographic Frequency (%) 
Gender 
Male 
Female 
 
102 (87.2) 
15 (12.8) 
Histology 
Adenocarcinoma 
Squamous Cell Carcinoma 
Neuro-endocrine 
 
110 (94.0) 
6 (5.1) 
1 (0.9) 
Degree of Differentiation 
Well 
Moderate 
Poor 
GX 
 
13 (11.1) 
40 (34.2) 
57 (48.7) 
7 (6.0) 
Radiological T-stage 
T1 
T2 
T3 
T4a 
 
12 (10.3) 
13 (11.1) 
83 (70.9) 
9 (7.7) 
Radiological N-stage 
N0 
N1 
N2 
N3 
 
58 (49.6) 
41 (35.0) 
14 (12.0) 
4 (3.4) 
Treatment Type 
NACT 
Surgery Alone 
NACRT 
 
67 (57.3) 
31 (26.5) 
19 (16.2) 
Tumour Regression Grade 
TRG 1 
TRG 2 
TRG 3 
TRG 4 
TRG 5 
 
9 (10.5) 
10 (11.6) 
11 (12.8) 
32 (37.2) 
24 (27.9) 
    
Operation Type 
Trans-hiatal oesophagectomy 
Ivor-Lewis oesophagectomy 
Total gastrectomy 
3-stage oesophagectomy 
Oesophago-gastrectomy 
 
56 (47.9) 
35 (29.9) 
22 (18.8) 
3 (2.5) 
1 (0.9) 
Circumferential Resection Margin 
Negative  
Positive 
 
66 (56.4) 
51 (43.6) 
GX unable to be assessed; NACT neo-adjuvant chemotherapy; NACRT neo-
adjuvant chemo-radiotherapy 
 
 
    
Table 2. Radiological and Pathological TN Staging Classification 
Frequency (%) CECT EUS PET/CT Pathology 
T0 0 (0.0) 0 (0.0) 0 (0.0) 9 (7.7) 
T1 12 (10.3) 12 (10.3) 0 (0.0) 18 (15.4) 
T2 22 (18.8) 13 (11.1) 0 (0.0) 9 (7.7) 
T3 73 (62.4) 83 (70.9) 0 (0.0) 71 (60.7) 
T4a 10 (8.5) 9 (7.7) 0 (0.0) 10 (8.5) 
TX 0 (0.0) 0 (0.0) 117 (100.0) 0 (0.0) 
Total 117 (100.0) 117 (100.0) 117 (100.0) 117 (100.0) 
N0 70 (59.8) 67 (53.7) 81 (69.2) 48 (41.0) 
N1 31 (26.5) 36 (30.8) 27 (23.1) 26 (22.2) 
N2 12 (10.3) 12 (10.3) 8 (6.8) 30 (25.6) 
N3 2 (1.7) 2 (1.7) 1 (0.9) 13 (11.1) 
NX 2 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 
Total 117 (100.0) 117 (100.0) 117 (100.0) 117 (100.0) 
TX/NX unable to be assessed 
 
 
    
Table 3. Association of EUS T-stage Groups and CRM involvement 
Frequency (%) CRM negative CRM positive Total 
EUS ≤T2 19 (16.2) 6 (5.1) 25 (21.4) 
EUS ≥T3 47 (40.3) 45 (38.4) 92 (78.6) 
Total 66 (56.4) 51 (43.6) 117 (100.0) 
 
 
    
Table 4. Results of Multi-Variate Binary Logistic Regression Model 
Variable Hazard Ratio (95% CI) p-value 
EUS ≤T2 vs ≥T3 5.188 (1.265-21.273) 0.022 
CT ≤T2 vs ≥T3 1.163 (0.398-3.397) 0.783 
PET MTL 0.633 (0.684-1.273) 0.652 
PET MTW 0.836 (0.445-1.570) 0.578 
SUVmax 0.989 (0.940-1.040) 0.655 
HR hazard ratio, CI confidence interval, MTL metabolic tumour length, MTW 
metabolic tumour width 
 
 
 
 
